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We demonstrate that metalloproteases in breast tumor microenvironments can inactivate reovirus. 51
Our findings expose that tumor microenvironment proteases could have negative impact on 52 proteinaceous cancer therapies such as reovirus, and that modification of such therapies to circumvent 53 inactivation by tumor metalloproteases merits consideration. 54 whether tumor-associated proteases have positive, negative, or neutral effects on reovirus infection of 115 tumor cells. 116
To determine the effects of tumor extracellular proteases on reovirus, we generated protease-117 enriched tumor extracellular extract (T.E.E.) from polyoma virus middle T-antigen-derived mouse 118 breast tumors by diffusion of extracellular content into phosphate-buffered saline (PBS). We then 119 exposed purified reovirus to T.E.E. and monitored reovirus protein processing by Western blot analysis. 120
As a positive control for protease-mediated reovirus uncoating, we also exposed purified reovirus to 121 intestinal extracellular extract (I.E.E.) prepared by flushing murine intestines with PBS. As anticipated, 122 I.E.E. treatment resulted in hallmarks of ISVP formation, including degradation of outer capsid protein 123 σ3, and cleavage of µ1C to δ ( Figure 1A ). I.E.E. treatment also led to cleavage of σ1 to the σ1N-tail 124 fragment. Despite processing of the outer capsid, the inner core proteins λ1/2 and σ2 remained intact; 125 this was anticipated since the reovirus core becomes transcription-competent and does not further 126 uncoat, but rather synthesizes and expels positive-sense RNA into the cytoplasm during virus 127 replication (35) . Importantly, following treatment with T.E.E., σ1 was cleaved to the 22 KDa σ1N 128 fragment. Cleavage of outer capsid µ1, which is a hallmark of ISVP generation, was however limited. 129
Core viral proteins were unaffected by T.E.E. treatment. The effects of T.E.E. were therefore distinct 130 from I.E.E, with T.E.E. causing cleavage of σ1 but failing to generate ISVPs. 131
Proteolytic processing of reovirus outer capsid proteins can depend on the concentration of 132 proteases, therefore we assessed the fate of reovirus proteins by western blot analysis after exposing 133 purified reovirus particles to increasing amounts of T.E.E. ( Figure 1B) . Furthermore, to determine if 134 reovirus processing was consistent among distinct T.E.E. samples, we obtained T.E.E. from two 135 independent mouse breast tumor explants. Cleavage of σ1 to σ1N was observed for T.E.E. obtained 136 from both mice, in a concentration dependent manner. Specifically, while all T.E.E. concentrations 137 effectively cleaved σ1 to σ1N, high T.E.E.-to-reovirus ratios caused further degradation of the σ1N 138 22kDa fragment. While core proteins were unaffected by T.E.E., outer capsid σ3 was degraded under 139 low ratios of T.E.E.-to-reovirus. This could possibly be a consequence of protease-inactivation at high 140 concentrations due to self-cleavage or cleavage by other proteases. Notably, however, under no 141 condition was µ1C processed to δ, suggesting that T.E.E. factors from multiple mice tumors did not 142 yield ISVPs. This is the first time, to our knowledge, that processing of reovirus by T.E.E. has been 143 characterized. 144
Since breast tumors have slightly acidic environments (36, 37) , we hypothesized that 145 incomplete processing of reovirus σ3 or µ1C by T.E.E. could be a result of poorly optimized pH 146 conditions. Therefore, reovirus was treated with T.E.E. at a range of pH conditions ( Figure 1C ). At highly 147 acidic pH (≤ 2), reovirus particles were degraded completely, as seen by the absence of all viral proteins 148 including core proteins λ1 and σ2. Cleavage of σ1 was most efficient above pH 6, with complete 149 conversion of σ1 to σ1N. Importantly, under no conditions that preserved reovirus core proteins (pH ≥ 150 2), was µ1C processed to δ. Overall, it seems that the optimal pH for reovirus processing was 6-7, 151 consistent with the environmental pH of most tumors (38, 39) . 152
To confirm that processing of reovirus proteins by T.E.E. was attributed to a protease, reovirus 153 was treated with T.E.E. from three independent mouse tumors but in the presence or absence of a 154 protease inhibitor cocktail (PIC) ( Figure 1D ). Processing of σ1 and σ3 was strongly impaired in the 155 presence of the PIC at all T.E.E.:reovirus ratios tested, implicating that a secreted protease in mouse 156 breast tumors is involved in cleavage of σ1 and occasional degradation of σ3. 157 158 Breast tumor extracellular protease(s) reduce reovirus attachment and decrease infectivity by 100-159 fold. 160
Having discovered that T.E.E. cleaves σ1 but does not produce ISVPs, it became important to 161 determine whether this partial processing of reovirus by T.E.E. affects infectivity. Specifically, the 162 cleavage of σ1 could be an important impediment to virus-cell attachment. Normally reovirus σ1 163 mediates attachment to cells through two domains: the head domain of σ1 mediates high-affinity 164 interaction with junction adhesion molecules (JAM-A), while the tail domain of σ1 supports association 165 with α2,3-, α2,6-, or α2,8-linked sialylated glycans (40). In the intestine, the luminal surface of 166 intestinal cells displays sialic acids (SA) but not JAM-A. Therefore, cleavage of σ1 and removal of the 167 JAM-binding head of reovirus by gut proteases trypsin and chymotrypsin is unlikely to impeded virus 168 binding to the SA-rich and JAM-A-deficient luminal face of intestinal epithelial cells. But JAM-A binding 169 may instead be necessary to mediate attachment at the JAM-rich basolateral side (41-43) of the 170 intestinal epithelium, where absence of proteases would maintain full-length σ1. Distinct from gut 171 epithelial cells, the levels of SA and JAM-A varies among tumor cells (44) (45) (46) (47) (48) . Accordingly, we queried 172 whether cleavage of σ1 to σ1N and consequential loss of JAM-binding affected attachment of reovirus 173 to non-epithelial cells. Equivalent particles of PBS-or T.E.E-treated reovirus were exposed to 174 tumorigenic L929 mouse fibroblast cells at 4 o C to permit attachment without entry. Cell-associated 175 particles were then enumerated by flow cytometric analysis using anti-reovirus antibodies (Figure 2A ). 176 A serial dilution of PBS-treated particles was used for quantitative purposes, and demonstrated a linear 177 relationship between particle number and cell attachment. T.E.E treatment reduced binding of 178 reovirus to L929 cells by ~80% ( Figure 2B ). 179
To determine the impact of T.E.E on infectivity, we then treated reovirus with T.E.E. versus PBS 180 and compared infectious titers (plaque forming units; pfu) on L929 cells commonly used to propagate 181 reovirus. T.E.E. from three independent mouse tumors reduced reovirus titers by ~100-fold relative to 182 the mock (PBS) treatment ( Figure 2C ). This finding was striking, as it suggests that tumor proteases may 183 pose a barrier to reovirus oncolytic potency by reducing virus infectivity. 184 185
Mechanistic explanation for loss of infectivity: Truncation of σ1 reduces binding by 100-fold in sialic 186

acid-low cells. 187
Since T.E.E treatment not only caused cleavage of σ1, but also sometimes cause degradation of 188 σ3 and perhaps other effects on protein conformations, it was important to directly determine if σ1 189 cleavage was necessary and sufficient for decreased reovirus binding. We therefore used reverse 190 genetics to generate reovirus particles with truncated σ1N fibers ( Figure 3A , T3D RG/σ1C ) that mimic σ1-191 cleavage by T.E.E. treatment without effects on σ3. We also generated wild-type reovirus (T3D RG ) by 192 reverse genetics to control for potential secondary effects of the reverse genetics system. In all 193 experiments, T3D and T3D RG behaved the same, demonstrating that reverse-genetics-generated virions 194 faithfully recapitulate the parental phenotype. Western blot analysis of CsCl-purified virus showed that 195 T3D RG/σ1C had truncated σ1N while T3D and T3D RG had full-length σ1 ( Figure 3B ). All three viruses had 196 equivalent relative levels of µ1C and σ3; therefore, any differences between these viruses can be 197 attributed to σ1 status. 198 If cleavage of σ1 by T.E.E was alone sufficient for reduced binding and infectivity observed in 199 should not be affected by T.E.E. treatment. Equivalent particles of T3D RG/σ1C versus T3D were 201 therefore assessed for cell-attachment in the presence or absence of T.E.E treatment using flow 202 cytometric analysis (Figure 3C and D) . First, T3D RG/σ1C exhibited reduced attachment relative to T3D 203 that mimicked levels observed with T3D treated with T.E.E. Second, while T3D binding reduced 204 following T.E.E treatment, attachment of T3D RG/σ1C to L929 cells was unaffected. The data implicates 205 cleavage of σ1 as the dominant contributing mechanism for reduced binding of reovirus following T. E.E 206 treatment. 207 Attachment efficiency was then tested on a panel of cancer cell lines that have differentially 208 express surface JAM and SA; for example, human cervical carcinoma (HeLa) cells and human breast 209 cancer (MDA-MB-231) cells were previously shown to have low JAM-but high SA-surface expression, 210 while L929 cells and the human breast cancer cell line MCF-7 to have low SA expression (48, 49) . Figure  211 3E shows a representative standardization of virus particles and Figure 3E a representative analysis of 212 T3D versus T3D RG/σ1C binding to MDA-MB-231. The binding assay was then repeated in five 213 independent experiments, and MFI for a given cell line normalized to T3D RG ( Figure 3G ). T3D RG/σ1C 214 exhibited a statistically significant reduction (~100-fold) in binding to SA-low L929 and MCF7 cells 215 relative to control viruses, suggesting that loss of the σ1 head domain is sufficient to make reovirus 216 dependent on SA for binding. Moreover, eliminating the JAM-binding σ1 domain in T3D RG/σ1C caused 217 reduced infectivity (i.e. frequency of cells stained positive for reovirus antigen) towards SA-low L929 218 and MCF-7 cells, but not towards SA-high HeLa cells ( Figure 3H ). 219
The relationship between SA levels and infectivity of reovirus with truncated σ1 was important 220 to validate, as it suggests that not only can the protease status of tumors impact reovirus infectivity, 221 but also the SA status of the tumor cell. We therefore tested two mouse (MTHJ and TUBO) and two 222 human (MCF7 and T47D) breast cancer cell lines for levels of SA versus reovirus attachment. Levels of 223 SA were measured by flow cytometry using fluorescence-labelled Sambucus nigra lectin (SNA). 224 Specificity of fluorescence for SA was confirmed by pre-treatment of cells with neurominidase ( Figure  225 3I). Note that in all cases, neurominidase strongly reduced SNA labelling but did not abolish signal 226 completely, which was expected because neurominidase activity is rarely complete. The four breast 227 cancer cell lines varied dramatically in SA levels, with MCF7 representing minimal SA and T47D maximal 228 SA levels relative to the rest ( Figure 3J ). Importantly, T3D RG/σ1C only exhibited reduced binding relative 229 to T3D when SA levels were low ( Figure 3K , MCF7 and MTHJ cells). Together, the findings strongly 230 support that truncation of σ1 reduces attachment of reovirus towards SA-low cells. 231 232
Reovirus-inactivating breast cancer proteases are metalloproteases. 233
Considerable research has demonstrated that tumor environments are rich in proteases of all 234 classes and that proteases can impact the fate of tumor growth, and metastasis (25, 50) . To elucidate 235 the class of protease(s) present in T.E.E. that acts on σ1 and σ3, reovirus was treated with T.E.E. in the 236 presence of protease inhibitors that target specific classes of proteases. Aprotinin, leupeptin, pepstatin 237 A, and E64D, were specifically used to inhibit serine, cysteine/serine/threonine, aspartyl and cysteine 238 proteases, respectively ( Figure 4A ). Since metalloprotease activity depends on metals as cofactors (51, 239 52), EDTA was used to chelate metal ions and therefore inhibit metalloproteases. The protease 240 inhibitor cocktail (PIC) was able to impair cleavage of σ1 and degradation of σ3, as demonstrated in 241 Figure 1D . Neither aprotinin nor leupeptin were capable of impairing σ1 cleavage and σ3 degradation. 242
Interestingly, Pepstatin A and E64 very minimally impaired σ1 cleavage, but strongly impaired 243 degradation of σ3. EDTA most drastically impaired proteolysis of both σ1 and σ3, suggesting that metal 244 ions are involved, and the dominant protease is a metalloprotease. 245
Next, we examined which protease inhibitors could reverse the loss of reovirus infectivity 246 caused by T.E.E. treatment ( Figure 4B ). Plaque titration was conducted on L929 cells similar to Figure 2 . 247
As seen previously, exposure of reovirus to T.E.E. caused a 100-fold decrease in infectious titers. 248
Neither aprotinin nor leupeptin were capable of rescuing infectivity, as expected given their inability to 249 prevent σ1 cleavage. Pepstatin A and E64 treatments partially rescued infectivity, which correlates with 250 their ability to partially prevent cleavage of σ1. We and others previously demonstrated that although 251 reovirus particles can hold up to 12 σ1 fibers, 3 or more fibers are necessary and sufficient to mediate 252 virus attachment (53, 54) . Accordingly, the maintenance of some full-length σ1 during pepstatin A and 253 E64 treatment ( Figure 4A ) explains why infectious titers remain high ( Figure 4B ). EDTA was able to fully 254 rescue infectivity, reinforcing that metal ions play a key role in T.E.E.-mediate proteolysis of reovirus σ1 255 and subsequent loss of infectivity towards SA-low cells. 256
Together the data suggests that pepstatin A-and E64-sensitive aspartyl and cysteine proteases 257 (respectively) partially contribute to σ1 cleavage, but that metalloproteinase(s) are the main culprits in 258 cleaving σ1 and reducing reovirus infectivity towards SA-low cells. 259 260
Breast cancer cells secrete proteases capable of cleaving σ1. 261
Proteases in the tumor microenvironment can come from multiple sources; from the tumor 262 cells, supporting fibroblasts, or innate and adaptive immune cells (25). To determine if tumor cells 263 directly release a protease that cleaves reovirus σ1 we collected the conditioned media from a panel of 264 cancer cell lines, filtered and concentrated the media 10X using 10 kDa -cutoff centricon columns, and 265 exposed reovirus to these 'medium extracellular extracts' (M.E.E.). The rationale for concentrating the 266 media was that cell culturing artificially dilutes extracellular factors by at least 100-fold and therefore 267 can strongly underestimate factor activity. For example, we culture 10 6 cells in 1ml of media, while 268
T.E.E and I.E.E are collected in 1ml for over 10 8 cells in tumors (55), which by itself is a dilution of 269 factors that would naturally be more concentrated. Therefore, we initially concentrated M.E.E by 10-270 fold and since we noted activity, we did not pursue further concentration. Also key to success of this 271 assay was the use of virus production-serum free medium (VP-SFM) to overcome the quenching effects 272 of fetal bovine serum proteins on protease activity. Also, the medium was collected after 3 independent cultures showed cleavage of σ1 to different extents, suggesting that the concentration of 280 proteases varies between cultures ( Figure 5C ). Overall, breast cancer cell M.E.E. recapitulated the 281 effects of T.E.E., indicating that tumor cells alone can secrete proteases that target reovirus σ1. Our 282 findings of course do not eliminate the possibility that supporting fibroblasts, or innate and adaptive 283 immune cells in tumor microenvironments also contribute additional reovirus-inactivating proteases. It 284 was interesting that neither lung cancer cell M.E.E. cleaved reovirus σ1. Although tempting to 285 speculate that tumor cell type (e.g., breast versus lung) may influence differential ability to inactivate 286 reovirus through secreted proteinases, a larger panel of lung cancer cells would be essential to make 287 such interpretation. 288
Reovirus was also treated with MCF-7 M.E.E in the absence or presence of ZnCl 2 , MgCl 2 , or 289 CaCl 2 to determine which metal ion promoted σ1 cleavage. With this stock of MCF-7 M.E.E., σ1 was 290 completely degraded rather than producing a stable σ1N fragment, as was described with high T.E.E. 291 concentrations ( Figure 1B) , so we therefore focused on the loss of full-length σ1 as our readout. 292 Importantly, degradation of σ1 was reproducibly increased in the presence of Zn 2+ , implicating a Zn-293 dependent MP in reovirus processing ( Figure 5D ). A time-course analysis showed that σ1 proteolysis 294 occurred rapidly by M.E.E. ( Figure 5E ), reaching maximum loss of full-length σ1 by 6 hours of 295 treatment, with Zn 2+ again promoting σ1 processing. A more detailed time course analysis shows 296 maximal proteolysis achieved already by 30-minute exposure of two independent preparations of 297 reovirus to MCF-7 M.E.E ( Figure 5F ). Together, the data suggest that breast cancer cells can themselves 298 secrete Zn-dependent metalloproteases that cleave σ1 with rapid kinetics. 299
Finally, we determined if xenograft tumors of MCF7 cells in severely immune-300 compromised NOD scid gamma mice (lacking mature T cells, B cells and natural killer cells) produced a 301 tumor microenvironment capable of cleaving reovirus σ1 ( Figure 5G ). At 45 days post-implantation, 302 excised tumors were rinsed twice in PBS, cut into 4 pieces, and incubated at 4 o C in 1 ml (total) PBS for 2 303 hours to diffuse extracellular content. These tumor extracellular extracts (T.E.E.) were clarified by 304 centrifugation and 0.45um filtration. Reovirus was then exposed to the T.E.E.s and loss of full-length σ1 305 was monitored by Western blot analysis ( Figure 5G ). Degradation of σ1 was T.E.E. dose-dependent and 306 varied from ~10-90% depending on the tumor. Four of the five T.E.E.s showed >60% cleavage. 307
Moreover, there seemed to be a relationship between the size of tumor and cleavage efficiency, 308 although many more samples would be required to strengthen the correlation. Since cleavage was 309 increased in the presence of Zn 2+ and decreased in the presence of EDTA, a Zn-dependent 310 metalloprotease is likely functioning in these tumors. However, since EDTA treatment did not 311 completely prevent cleavage, it is also possible that additional ion-independent σ1-degrading 312 proteases were active in MCF7 tumors. These experiments confirm the presence of σ1-cleaving 313 metalloproteases in tumors in vivo, and in absence of T-, B-, or NK-cell sources. 314 315
Mutation of the σ1 neck domain overcomes reovirus cleavage by breast cancer metalloprotease. 316
Given that proteolysis of reovirus σ1 by Zn-dependent metalloproteases secreted by human 317 breast cancer cells and present in mouse breast cancer tumors diminished reovirus binding and 318 infection towards SA-low tumor cells, we next sought to modify reovirus σ1 to overcome cleavage. 319 Proteolysis of reovirus by intestinal proteases chymotrypsin and trypsin was previously shown to occur 320 in the flexible protease-hypersensitive "neck" region (residues 219-264) between the tail and the head 321 domains of σ1 (56, 57) ( Figure 6A ). We reasoned that if tumor-associated metalloproteases also 322 cleaved in the σ1 neck domain, then the σ1N fragments generated by T.E.E., I.E.E., trypsin, and 323 chymotrypsin should share a similar molecular weight. Indeed, the tail (σ1N) and head (σ1C) fragments 324 detected by Western blot analysis with σ1N-and σ1C-specific antibodies (respectively) were similar 325 when reovirus was treated with T.E.E., I.E.E., trypsin, or chymotrypsin ( Figure 6B ). The shorter 326 fragments of σ1 under some conditions of I.E.E and chymotrypsin treatment is likely to reflect further 327 cleavage at the extreme N-terminus as described previously (58, 59) . Importantly, since chymotrypsin 328 and trypsin cleavage sites are six amino acids apart but the size of their σ1 cleavage fragments are not 329 resolved by our assay, we can infer that the tumor-associated MP cleaves in the same general vicinity 330 as the gut proteases. 331
It was previously observed that a change from threonine to isoleucine at position 249 of σ1 can 332 prevent cleavage by both chymotrypsin and trypsin despite their different cleavage locations in the 333 neck domain (56). These findings suggested that the T249I modification eliminated cleavage 334 susceptibility by altering the secondary structure of the neck domain, thereby altering the exposure of 335 the hyper-cleavage domain. Accordingly, we tested if mutation of T249 to isoleucine could also prevent 336 cleavage by tumor-associated metalloproteases. Using reverse genetics, we introduced the T249I 337 mutation into T3D and assessed the fate of σ1 T249I after treatment with I.E.E. ( Figure 6C ) or T.E.E. 338
( Figure 6D ). The T249I mutation successfully impeded cleavage of σ1 by both I.E.E. and T.E.E. 339
Our previous studies showed that a mutation in the domain that anchors σ1 in virions, σ1-S18I, 340 reduces the number of σ1 fibers per reovirus particle to ~4 (instead of 12 on wild-type T3D). We and 341 others further showed that 3 σ1 929 and other 342 tumorigenic cells. Moreover, having 4-7 (but fewer than 12) σ1 trimers promotes uncoating of σ1 343 during virus entry into tumor cells, and thereby increases reovirus oncolysis in vitro and in vivo (53, 60) . 344
Having now learned that σ1 undergoes cleavage by breast tumor-associated metalloproteases, we 345 reasoned that having fewer σ1 fibers would make T3D S18I hypersensitive to tumor-associated protease 346 inactivation; in other words, that maintaining full-length σ1 would become less-likely if there were 347 fewer σ1 fibers to begin with. We therefore also incorporated the T249I mutation into T3D S18I to 348 generate a double-mutant T3D S18I/T249I . As expected, both T3D S18I and T3D S18I/T249I showed lower σ1 349 levels relative to T3D or T3D T249I (Figure 6C and 6D ). Importantly however, while σ1 of T3D S18I was 350 cleaved by I.E.E. and T.E.E., the σ1 T3D S18I/T249I was refractory to cleavage by either extracellular extract. 351
In summary, localizing the σ1 cleavage site to the neck domain, and subsequently introducing a T249I 352 mutation, allowed us to successfully generate T3D and T3D S18I variants that withstand proteolysis by 353 breast tumor-associated metalloproteases. 354 Chappell et al (1998) previously found that clinical reovirus strains exhibit either a threonine or 355 isoleucine at position 249 of σ1 (56), but it was unknown whether a T249I mutation would have 356 undesired determinantal effects on virus entry, endocytosis, or uncoating. To test this, L929 cells were 357 exposed to equivalent particle doses of T3D, T3D T249I , T3D S18I or T3D S18I/T249I at 4 o C, washed extensively, 358 then incubated at 37 o C for 0-9 hours. At every hour, cells were fixed, stained for specific reovirus 359 proteins, then analyzed by flow cytometry to follow the fate of input reovirus particles versus de novo 360 reovirus protein expression. First, flow cytometry with λ2-specific antibodies, which cannot detect 361 input virions (i.e., λ2 epitopes are hidden in the virion) but can detect de novo λ2 protein expression, 362 demonstrated new virus protein expression at 8 hours post-infection (hpi). Importantly, T3D and 363 T3D T249I demonstrated similar de novo protein synthesis levels, suggesting similar kinetics of infection 364 ( Figure 6E ). T3D S18I was similar to T3D S18I/T249I with respect to de novo λ2 expression. As expected from 365 previous studies showing that S18I increases reovirus infectivity (53, 60), both T3D S18I and T3D S18I/T249I 366 exhibited ~3-fold more de novo λ2 expression relative to T3D and T3D T249I . 367
Next, polyclonal anti-reovirus antibodies and monoclonal antibodies towards σ3 that detect 368 both input virions and de-novo virus protein synthesis, confirmed equivalent input levels for all four 369
viruses, yet increased infectivity (or rate of infectivity) of variants containing the previously-370 characterized S18I mutation ( Figure 6F ). Again, it is important to note that the T249I mutation did not 371 impact the efficiency of establishing infection. Finally, antibodies directed to the tail domain of σ1 372 confirmed that input virions containing the S18I mutation contained ~3-fold less σ1 but produced more 373 de-novo proteins ( Figure 6G ). Altogether these results indicate that the T249I mutation does not 374 negatively affect T3D reovirus infection whether in the context of wild-type T3D or the more oncolytic 375 T3D S18I variant. 376
Since cleavage of σ1 by T.E.E. reduced attachment to SA-low cells and inhibited infectivity 377 ( Figure 2 and 3) , we evaluated if the T249I mutation that prevents σ1 cleavage can facilitate reovirus 378 infectivity in the presence of MPs. Accordingly, L929 cells were exposed to equivalent doses of T3D, 379 T3D T249I , T3D S18I or T3D S18I/T249I that had been pretreated with T.E.E., then binding was evaluated by 380 flow cytometry ( Figure 6H ), and infectivity evaluated by plaque assays (Figure 6I ). T3D T249I bound to 381 L929 cells 16X more than T3D ( Figure 6H ), indicating that it was resistant to protease cleavage. This 382 increase in binding correlated with 16X higher virus production than T3D ( Figure 6I ). T3D S18I showed 383 lower binding and virus production than T3D probably because this mutant has reduced σ1 levels and 384 is therefore hypersensitive to σ1 cleavage. Importantly, the dysfunction in binding and virus production 385 was overcome by combining with the T249I mutation in T3D S18I/T249I . These results suggest that 386 incorporating the T249I mutation into T3D generates a virus capable of resisting T.E.E. 387 388 T3D T249I and T3D S18I/T249I do not have added toxicity relative to T3D in vivo. 389
Clinical trials using T3D as a monotherapy in several cancers have shown that T3D is a safe 390 therapy but would benefit from enhanced efficacy (61). Little is known about the effects of the tumor 391 environment on reovirus oncolytic performance. Having found that T.E.E. cleaves σ1 and reduces 392 infectivity towards tumor cells with low sialic acid levels (Figure 3) , and having developed σ1-393 "uncleavable" variants of T3D (T3D T249I and T3D S18I/T249I ) ( Figure 6 ), suggests that uncleavable reovirus 394 may warrant consideration for testing as oncolytic agents. The first priority, however, was to 395 determine if these mutants were safe. Previous studies found that JAM-A on endothelial cells 396 contributed to bloodstream dissemination of serotype 1 reovirus (62), so it seemed essential to test if 397 T3D T249I and T3D S18I/T249I , by virtue of retaining JAM-A binding, pose any toxicity / safety concerns 398 relative to T3D. 399
While reovirus is restricted to tumors and safety has been demonstrated in immunocompetent 400 mice and in humans in clinical trials, reovirus shows visible signs of toxicity in severely immune-401 compromised NOD scid gamma (NSG) mice. NGS mice lack mature T cells, B cells and natural killer (NK) 402 cells. In the absence of immune restrictions, T3D reovirus can disseminate from tumors to heart and 403 circulatory systems, impair circulation, and cause black-foot syndrome (63). We therefore tested the 404 toxicity of T3D strains when injected into MCF7 tumor xenografts in the background of NSG mice. 405
Specifically, MCF7 cells were implanted into the mammary fat pads of NSG mice. When tumors became 406 palpable, five mice were injected intratumorally with either PBS, or 10 6 plaque-forming-units (PFUs) of 407 T3D, T3D T249I , T3D S18I or T3D S18I/T249I . The dose was chosen based on our preliminary dose escalation 408 experiments with T3D, which defined 10 6 as an optimal dose to see toxicity within guidelines of strict 409 animal care protocols (data not shown). Reovirus injections were repeated for a total of three times 410 over a one-week period. Mice were monitored and euthanized based on humane endpoints (first sign 411 of black tail/black foot, or over 15% weight loss). The onset of symptoms of toxicity for the different 412 treatment groups is shown in Figure 7A . Although time to symptoms varied between 25 and 32 days 413 after the first virus inoculation, there were no significant differences among the virus treatments with 414 respect to appearance of symptoms. PBS-treated animals did not exhibit symptoms of toxicity and 415 were euthanized at 45 days. Reovirus titers in the hearts were not significantly different between 416 groups ( Figure 7B ). Therefore, in the NSG model of reovirus toxicity in absence of sufficient immune 417 restriction, the σ1-uncleavable T3D variants did not pose additional toxicity or safety concerns relative 418 to wild-type T3D. 419
The onset of black-foot syndrome necessitates euthanasia, which prevented assessment of 420 virus-mediated increase in long-term survival of MCF7 tumor-bearing mice. However, since tumors 421 were available to us upon euthanasia, we did assess the relative infectious virus titers of σ1-422 uncleavable T3D variants versus wild-type T3D in tumors. The mean reovirus titers in homogenized 423 tumors were 1.0×10 7 , 1.6×10 8 , 1.8×10 8 , and 3.5×10 8 PFUs for T3D, T3D T249I , T3D S18I and T3D S18I/T249I 424 respectively ( Figure 7C ). While the trend suggested increasing titers for progressive addition of T249I 425 and S18I mutations, statistical significance was only achieved for T3D S18I/T249I versus T3D, which showed 426 a 30-fold difference (p=0.0167). As explored further in the discussion, these studies were designed to 427 monitor safety, and therefore distinct in vivo experimental designs beyond the scope of this study 428 would be necessary in future to compare oncolytic properties of these T3D variants. The current 429 animal experiment supports that T3D S18I and T3D S18I/T249I do not exhibit gain of function with respect to 430 virulence when introduced intra-tumorally. Moreover, the inactivation of reovirus by breast cancer-associated MPs could be fully overcome by 455 introducing a mutation (T249I) into σ1. Reovirus with the σ1 T249I mutation did not exhibit added toxicity 456 in immunocompromised NSG mice, and can therefore proceed to testing for oncolytic activity in 457 immunocompetent breast cancer models. Conceptually, our findings extend beyond reovirus, 458
suggesting that tumor-associated proteases warrant consideration when using proteinaceous therapies 459 in general. 460
Proteases are prevalent components of the tumor microenvironment, participating in 461 extracellular matrix degradation, tumor cell invasiveness, as well as altering activities of important 462 signaling molecules (64). Many cells contribute to the pool of proteases in tumors, including the tumor 463 cells themselves, mesenchymal stem cells, tumor-supporting fibroblasts and endothelial cells, and both 464 innate and adaptive immune cells. In our studies, we discovered that breast cancer cells can secrete 465 reovirus-inactivating proteases into the medium; but our findings do not preclude the possibility that 466 other cells contribute additional proteases that act on reovirus in vivo. It would be interesting to 467 expose reovirus to medium from tumor-supporting cells and immune cells, to determine whether the 468 composition of a specific tumor could predict reovirus processing/infectivity at the tumor site. 469
Nevertheless, the extracellular extracts from two distinct in vivo breast tumor models (i.e. MCF7-470 derived tumors and polyoma virus middle T-antigen-derived tumors) produced the same outcome as 471 media derived from breast cancer cells: an absence of the beneficial processing of reovirus to ISVPs, 472 but rather inactivation of reovirus infectivity towards sialic-acid-low tumor cells by cleavage of σ1. Our 473 preliminary analysis showed that unlike breast cancer cells, two lung cancer cell lines failed to secrete 474 proteases that process reovirus. An analysis of a larger panel of lung and other cancer cell lines would 475 be necessary, however, to determine if the inactivation of reovirus is breast-cancer-specific, or can 476 extend to other cancers. 477
Human proteases are categorized into aspartic, cysteine, metallo, serine, or threonine protease 478 classes, on the basis of the catalytic amino acid (or ion) in the active site. To distinguish which class(es) 479 of proteases cleave σ1, reovirus processing by breast cancer proteases was tested in the presence of 480 pharmacological inhibitors or divalent ions. The experiments indicate that the primary protease activity 481 that cleaves σ1 is a zinc-dependent metalloprotease. As there are 100s of possible candidates, and 482 specific pharmacological inhibitors are only available for a select few, it requires a proteomics 483 approach in the future to identify the precise protease that cleaves σ1. The identity of the protease 484 cannot be determined from the sequence of σ1 due to lack of defined linear consensus sequences for 485 most candidates and yet unclear preferences for specific substrate secondary and tertiary structures. 486
Moreover, it is important to note that our experiments also implicated aspartyl and cysteine proteases 487 as having partial effects on σ1 cleavage and reovirus infectivity (Figure 4) . A remarkable feature of the 488 tumor proteolytic network is the large extent to which proteases cleave other proteases and thereby 489 affect their activities. For example, many metalloproteases are themselves substrates of aspartic, 490 cysteine, and serine proteases (64). It is therefore possible that aspartyl and cysteine proteases cleave 491 σ1 directly, or, that they contribute to activation of the key metalloprotease. If the precise protease(s) 492 that cleave σ1 are identified, it would be interesting to test if they serve as predictive markers for the 493 extent of reovirus amplification in breast tumors. Given the complexity of the proteolytic network, we 494 instead focused our attention on characterizing the effects of the protease on reovirus, and modifying 495 reovirus to withstand the protease(s) irrespective of their identity. 496 Another interesting detail from our studies is that breast cancer MPs make reovirus dependent 497 on sialic acids (SA), and therefore reduce reovirus binding and infection specifically in SA-low breast 498 cancer cells such as MCF-7. SAs are frequently modified in BC (65), for example with overexpressed 499 complex β-1,6-branched glycans (66), incomplete glycan structures (67), or non-mammalian 500 'xenoglycans' (68). Hypersialylation is frequently seen in highly-invasive breast cancers, which increases 501 shedding of SAs that could occlude SA binding sites on the virion. To fully appreciate the effects of σ1 502 cleavage on reovirus oncolysis in breast cancer, it seems necessary to better understand which sialic 503 acid modifications impact reovirus infection, and whether shed SAs compete for reovirus attachment 504 to cells. The nature of SAs in specific cancers could then potentially serve as predictive markers for 505 reovirus amplification. In any case, by overcoming σ1 cleavage with a T249I mutation, the retention of 506 JAM-A binding capacity may overcome barriers posed by SA insufficiency or soluble SA competition. 507
As for application of knowledge towards improving reovirus oncolysis, our findings suggest a 508
compendium of possibilities to be tested in the future. First, the T3D T249I and T3D S18I/T249I variants need 509 to be thoroughly compared to T3D parental virus in various in vivo animal models, to appreciate the 510 extent to which cleavage of σ1 by tumor proteases affects oncolysis. Next, we propose that 511 modification of T3D to transition to ISVPs in the context of well-characterized tumor proteases could 512 be dually beneficial. Others have previously proposed using ISVPs (rather than whole reovirus particles) 513 for cancer therapy (69); but such a procedure would only benefit infection for the incoming inoculum. 514
Having reovirus consistently transition to ISVPs in tumor environments should produce a benefit at 515 every round of virus amplification. Another idea is to generate reovirus particles that encode natural 516 metalloprotease inhibitors, such as the small tissue inhibitors of metalloproteinase (TIMPs). 517
Metalloproteases have served as possible cancer therapeutic targets, but unfortunately they also play 518 important roles in healthy tissues and therefore global inhibition can be toxic. Perhaps a virus that 519 directly delivers TIMPs to tumor microenvironments could serve two functions; inhibit inactivation of 520 the virus, and prevent pro-tumor activities of MPs. Finally, our findings could extend beyond reovirus, 521 as there are many oncolytic viruses and other proteinaceous treatments such as antibodies undergoing 522 clinical testing and use for cancer therapy. An expanded understanding of the effect(s) of tumor 523 proteases on proteinaceous treatments could help develop second generation therapies with 524 augmented potencies. 525
Finally, beyond implications on reovirus oncolysis, our finding that proteases in tumor versus 526 intestinal microenvironments exhibit different on reovirus demonstrates that virus-host interactions 527 are not just limited to the target infected cells, but to the entire environment of a niche. In other 528 words, if we better understand extracellular host factors that impact viruses, we may better appreciate 529 why viruses thrive in specific host niches. In addition to proteases, extracellular factors such as the 530 microbiota and immunological host factors can impact viruses. It will be interesting to know whether 531 additional extracellular factors such as the extracellular matrix, secreted lipids, carbohydrates, enzymes 532 or other soluble factors impact the dynamics of viruses and therefore their oncolytic or pathogenic 533 potential. 534 535 536 537 538
Materials and Methods:
539 Reovirus production: Mammalian Orthoreovirus Serotype 3 Dearing (T3D) was propagated in L929 540 spinner cultures, extracted, and CsCl purified as previously described (70). Virus titers were determined 541 by plaque assay on L929 cells as previously described (71). The titer of the stock virus used in most 542 experiments was 1.01x10 10 PFU/mL. 543 544 Cell culture: L929 cells were cultured in minimal essential medium (MEM) (Sigma) supplemented with 545 10% FBS (Sigma), 1× sodium pyruvate (Sigma), non-essential amino acids (NEAA) (Sigma), and 1× 546 Antibiotic-Antimycotic (Gibco, catalogue #15240062). HeLa cells were cultured in Dulbecco's minimal 547 essential medium (DMEM) and 1× Antibiotic-Antimycotic. MCF-7, T47D, MB-468, MB-231, H1299, A549 548 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (supplemented as 549 described for MEM). L929, Hela, and A549 cells were laboratory stocks obtained from Dr. Patrick Lee's 550 laboratory (Dalhousie University), while remaining cells were purchased from the American Type 551 Culture Collection; all cells were confirmed mycoplasma free by Hoechst DNA Staining. For 552 experiments, cells were cultured in 1ml per well of a 12 well plate, and media was scaled according to 553 the surface area (for example, in a well of a 6 well plate, we used 2ml of media). 554 555 Preparation of protease rich extracts: To mimic the tumor and intestinal environments reovirus would 556 encounter, we obtained extracellular extracts from both environments. Tumor extracellular extract 557 (T.E.E.) was generated by establishing breast tumors in mice from polyoma virus middle T-antigen 558 derived tumor cells (72). Tumors were explanted and incubated in 1ml phosphate buffered saline at 559 4°C for 2 hours. The PBS solution was then centrifuged at 10,000 × g and filtered (0.45µm) to reduce 560 cellular debris. I.E.E was made by flushing entire murine intestines with 1ml PBS followed by filtering 561 (0.45µm) to remove debris. Polyoma virus middle T-antigen Tumor sizes ranged from 700-2000mm 2 . 562
The same method was used to extract T.E.E. from MCF7 tumors in Figure 5G , except tumors were 563 smaller and therefore diffused into 0.5ml of PBS (tumor sizes indicated in Figure) . To determine 564 whether cancer cells alone are capable of secreting proteases that inactivate reovirus, protease-rich 565 extracellular extract was obtained from a variety of breast and lung cancer cell lines 566 T47D, MB-468, MB-231; Lung-H1299, A549) for 24 hours at 37°C (M.E.E; media extracellular extract) 567 using the following protocol: First, cells were cultured to 80% confluent as described above. After an 568 overnight incubation, the supplemented RPMI medium was replaced with protein-free VP-SFM (Virus 569 Production Serum Free Media) supplemented with L-glutamine, and the cells were then cultured for 3 570 days; health of cells with limited cell detachment was confirmed daily by microscopy. The medium was 571 then collected and centrifuged at 1000 x g for 7 minutes to remove any floating cells and debris. The 572 supernatants were passed through a 0.45μm low protein binding syringe filter. Then, the filtrate was 573 centrifuged in a 5K NMWL (nominal molecular weight limit) centrifugal filter (Millipore UFV4BCC00) at 574 3000RPM for 5-10 minutes, until volume reached 1/10 th initial volume. For use as a negative control, a 575 plate containing supplemented RPMI medium without any cells was subjected to the same procedure. figures, but ranged from 1-15µl of extract at original concentration, and 1.08x10 10 to 5.40x10 10 viral 584 particles (1-5µl of reovirus, at a concentration of 1.08x10 13 particles/mL, as calculated based on the 585 equivalency that a spectrophotometric optical density of 260 nm (OD 260 ) of 5.42= 1.13x10 13 particles). 586
The proteolysis assay was conducted in PCR tubes and incubated using a Bio-rad T100 Thermal Cycler 587 (with heated lid). For the timepoint digests Bio-rad S1000 and C1000 thermal cyclers were also used. 588
Reactions were incubated at 37 o C for 24 hours, or for the time lengths indicated during timecourse 589 analyses. The inhibitors used were EDTA (ethylenediaminetetraacetic acid at 36.25μM), EDTA-free confirm that at the same dilution, there was equivalent levels of virus proteins and therefore 945 equivalent numbers of T3D, T3 RG and T3D RG/σ1C purified viruses used for binding assessment. (F) 946
Example of flow cytometry to quantify attachment of T3D and T3D RG/σ1C to MDA-MB-231 cells. To 947 determine relative binding of T3D RG/σ1C to T3D, the MFI of the peak from T3D RG/σ1C at 1× dilution 948 produced was extrapolated based on the standard curve generated for T3D. (G) Binding assay with 949 T3D PL and T3 RG versus T3D RG/σ1C reovirus on HeLa, MDA-MB-231, L929, MCF7 cells. Mean fluorescence 950 intensity (MFI) was set to 100% for T3D RG on a given cell line, and remaining virus MFIs presented as a 951 percentage of binding relative to T3D RG . Results depict five independent experiments, with 2-way 952 ANOVA statistical analysis and Dunnet's multiple comparison test. (H) Infectivity of T3D, T3 RG and 953 T3D RG/σ1C in cancer cell lines with different expression levels of JAM and SA, as indicated. Reovirus 954 infection was detected by immunocytochemistry using a polyclonal anti-reovirus serum. Panels shown 955 are representative of two independent experiments (I) Sialic acid surface expression detected with 956 fluorophore-labelled SNA for MCF7, MTHJ, TUBO and T47D breast cancer cells. Neurominidase 957 treatment versus untreated cells was used to confirm specificity of SNA staining for sialic acids. (J) 958
Mean fluorescence Intensity for SNA staining relative to unstained controls (SNA minus mock), similar 959 to (I), for 2-3 independent experiments. *p<0.05, **p<0.001, ANOVA with Tukey's multiple 960 comparisons test. (K) Mean fluorescence intensity measures the relative particle attachment for T3D 961 versus T3D RG/σ1C on MCF7, MTHJ, TUBO and T47D breast cancer cells. Similar calculation as (G) for 2 ZnCl 2 for 6, 12, 18 and 24 hours and preservation of full length σ1 assessed by western blot analysis. (F) 983
To ensure that susceptibility to MCF-7-mediated digestion of σ1 was independent of the reovirus 984 preparation, two independently-purified reovirus stocks were treated with MCF-7 M.E.E. or PBS for 0.5 985 to 6 hours (as indicated), and preservation of full length σ1 assessed by western blot analysis. (G) MCF7 986 tumors implanted into NSG mice were excised after 45 days of in vivo tumor growth and T.E.E. was 987 prepared. Reovirus was treated with 1x and 2x T.E.E., or 2x T.E.E in presence of EDTA or ZnCl 2 and 988 subjected to Western blot analysis. Densiometric analysis of full-length σ1 is provided below the blot 989 relative to PBS treated reovirus. 990 991 CsCl-purified T3D, T3D T249I , T3D S18I or T3D S18I/T249I were treated with (C) PBS, I.E.E or (D) T.E.E. for 24 996 hours at 37°C. Western blot analysis with both polyclonal anti-reovirus antibodies and σ1N-specific 997 antibodies demonstrate the levels of full-length σ1 and σ1N. (E-G) Reovirus infection dynamics of T3D, 998 T3D T249I , T3D S18I or T3D S18I/T249I viruses. Flow cytometry was used to evaluate expression of reovirus 999
